$PRME
Prime Medicine Inc Stock $prme

$prme Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000162828023007266 Filed on March 09, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.153M	$9.625M	$29.82M
YoY Change	47.13%	33.92%	114.16%
% of Gross Profit
Research & Development	$30.88M	$29.06M	$86.73M
YoY Change	125.78%	-45.05%	22.93%
% of Gross Profit
Depreciation & Amortization	$1.052M	$870.0K	$2.200M
YoY Change	259.04%	279.91%	287.32%
% of Gross Profit
Operating Expenses	$40.03M	$38.69M	$116.5M
YoY Change	101.19%	-35.6%	37.96%
Operating Profit	-$40.03M		-$116.5M
YoY Change	101.19%		37.96%
Interest Expense	-$1.701M	-$1.709M	-$8.128M
YoY Change	-62.07%	16.58%	1978.77%
% of Operating Profit
Other Income/Expense, Net	$434.0K	$926.0K	-$6.225M
YoY Change	3845.45%	7616.67%	-92.31%
Pretax Income	-$39.60M	-$39.47M	-$122.8M
YoY Change	62.48%	-35.85%	-25.98%
Income Tax	-$202.0K	-$186.0K	-$948.0K
% Of Pretax Income
Net Earnings	-$39.40M	-$40.60M	-$121.8M
YoY Change	31.04%	-41.4%	-33.84%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.44		-$4.19
Diluted Earnings Per Share	-$0.44	-$0.38	-$4.19
COMMON SHARES
Basic Shares Outstanding	97.25M shares	97.21M shares	33.89M shares
Diluted Shares Outstanding	89.06M shares		33.89M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$243.4M	$286.1M	$293.9M
YoY Change	15.2%	6.11%	9.01%
Cash & Equivalents	$133.5M	$187.6M	$187.6M
Short-Term Investments	$109.9M	$98.47M	$106.3M
Other Short-Term Assets	$3.982M	$2.697M	$2.697M
YoY Change	477.1%	181.23%	181.23%
Inventory
Prepaid Expenses		$2.451M
Receivables
Other Receivables
Total Short-Term Assets	$253.5M	$296.6M	$296.6M
YoY Change	19.6%	9.62%	9.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.59M	$19.01M	$48.55M
YoY Change	37.81%	21.25%	209.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.646M	$1.646M	$15.14M
YoY Change	-90.28%	-89.45%	-2.93%
Total Long-Term Assets	$63.45M	$63.70M	$63.70M
YoY Change	94.65%	103.65%	103.65%
TOTAL ASSETS
Total Short-Term Assets	$253.5M	$296.6M	$296.6M
Total Long-Term Assets	$63.45M	$63.70M	$63.70M
Total Assets	$316.9M	$360.3M	$360.3M
YoY Change	29.6%	19.37%	19.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.561M	$4.332M	$4.332M
YoY Change	42.71%	201.88%	201.88%
Accrued Expenses	$7.543M	$10.69M	$20.39M
YoY Change	-12.39%	-75.45%	-53.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$23.87M	$26.71M	$26.71M
YoY Change	85.19%	-53.93%	-53.93%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$14.20M	$17.05M	$17.05M
YoY Change	578.63%	455.41%	455.41%
Total Long-Term Liabilities	$14.20M	$17.05M	$17.05M
YoY Change	578.63%	455.41%	455.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.87M	$26.71M	$26.71M
Total Long-Term Liabilities	$14.20M	$17.05M	$17.05M
Total Liabilities	$38.15M	$44.04M	$44.04M
YoY Change	143.07%	-29.3%	-29.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$332.6M	-$293.2M
YoY Change		71.09%
Common Stock	$2.000K	$2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$278.8M	$316.3M	$316.3M
YoY Change
Total Liabilities & Shareholders Equity	$316.9M	$360.3M	$360.3M
YoY Change	29.6%	19.37%	19.37%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$39.40M	-$40.60M	-$121.8M
YoY Change	31.04%	-41.4%	-33.84%
Depreciation, Depletion And Amortization	$1.052M	$870.0K	$2.200M
YoY Change	259.04%	279.91%	287.32%
Cash From Operating Activities	-$41.56M	-$30.71M	-$131.8M
YoY Change	-18.18%	132.9%	286.79%
INVESTING ACTIVITIES
Capital Expenditures	$1.999M	$4.814M	$16.10M
YoY Change	18.42%	1160.21%	287.83%
Acquisitions
YoY Change
Other Investing Activities	-$10.67M	-$8.873M	-$31.00M
YoY Change	-132.74%	-170.78%	-55.38%
Cash From Investing Activities	-$12.67M	-$13.69M	-$47.10M
YoY Change	-141.0%	-212.61%	-36.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$68.00K	184.1M	$181.5M
YoY Change	-105.35%	-17049.63%	-32.6%
NET CHANGE
Cash From Operating Activities	-$41.56M	-30.71M	-$131.8M
Cash From Investing Activities	-$12.67M	-13.69M	-$47.10M
Cash From Financing Activities	$68.00K	184.1M	$181.5M
Net Change In Cash	-$54.16M	139.7M	$2.571M
YoY Change	155.8%	-6691.46%	-98.41%
FREE CASH FLOW
Cash From Operating Activities	-$41.56M	-$30.71M	-$131.8M
Capital Expenditures	$1.999M	$4.814M	$16.10M
Free Cash Flow	-$43.56M	-$35.53M	-$147.9M
YoY Change	-17.0%	161.82%	286.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001894562
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.32167
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41536
CY2022	dei	Entity Registrant Name EntityRegistrantName	PRIME MEDICINE, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3097762
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	21 Erie Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2022	dei	City Area Code CityAreaCode	(617)
CY2022	dei	Local Phone Number LocalPhoneNumber	564-0013
CY2022	dei	Security12b Title Security12bTitle	Common stock, par value $0.00001 per share
CY2022	dei	Trading Symbol TradingSymbol	PRME
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	0	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	97245827	shares
CY2022	dei	Auditor Firm AuditorFirmId	238
CY2022	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187620000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	185420000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	98467000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	68238000	usd
CY2022Q4	prme	Short Term Investments Related Parties ShortTermInvestmentsRelatedParties	7834000	usd
CY2021Q4	prme	Short Term Investments Related Parties ShortTermInvestmentsRelatedParties	15962000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2697000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	959000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	296618000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	270579000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19009000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4932000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29545000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10746000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13496000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13125000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1646000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2474000	usd
CY2022Q4	us-gaap	Assets Assets	360314000	usd
CY2021Q4	us-gaap	Assets Assets	301856000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4332000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1435000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10688000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	37192000	usd
CY2022Q4	prme	Related Party Forward Contract Liability Current RelatedPartyForwardContractLiabilityCurrent	0	usd
CY2021Q4	prme	Related Party Forward Contract Liability Current RelatedPartyForwardContractLiabilityCurrent	12020000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11694000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7336000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26714000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	57983000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17051000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3070000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	279000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1243000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	44044000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	62296000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	293258790	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97209213	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97209213	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32413860	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32413860	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	609849000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	15163000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-384000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-27000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-293197000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171376000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	316270000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-156240000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	360314000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	301856000	usd
CY2022Q4	prme	Related Party Transaction Accrued Liabilities Current RelatedPartyTransactionAccruedLiabilitiesCurrent	300000	usd
CY2021Q4	prme	Related Party Transaction Accrued Liabilities Current RelatedPartyTransactionAccruedLiabilitiesCurrent	30000000	usd
CY2021Q4	prme	Related Party Forward Contract Liability Current RelatedPartyForwardContractLiabilityCurrent	12000000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5210000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	86725000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70550000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2980000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29819000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13924000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3162000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	116544000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	84474000	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	6142000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-116544000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-84474000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-932000	usd
CY2022	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	0	usd
CY2021	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	-74319000	usd
CY2020	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	-10904000	usd
CY2022	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	0	usd
CY2021	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	-6681000	usd
CY2020	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	-700000	usd
CY2022	prme	Change In Fair Value Of Related Party Short Term Investment ChangeInFairValueOfRelatedPartyShortTermInvestment	-8128000	usd
CY2021	prme	Change In Fair Value Of Related Party Short Term Investment ChangeInFairValueOfRelatedPartyShortTermInvestment	-391000	usd
CY2020	prme	Change In Fair Value Of Related Party Short Term Investment ChangeInFairValueOfRelatedPartyShortTermInvestment	10867000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1903000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	126000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6225000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-81379000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-611000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-122769000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-165853000	usd
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-1543000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-948000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-486000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1867000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-165367000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3410000	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1468000	usd
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1645000	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	20193000	usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	17284000	usd
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-142014000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-142014000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-184119000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-184119000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5055000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5055000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.19
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.19
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.19
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.19
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.91
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.91
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33891264	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33891264	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12973495	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12973495	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2639717	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2639717	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-165367000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3410000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-357000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-27000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-357000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-27000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-122178000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-165394000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3410000	usd
CY2020	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	150000	usd
CY2021	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	42170000	usd
CY2020	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	126000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-2598000	usd
CY2020	prme	Adjustments To Additional Paid In Capital Temporary Equity Stock Issued During Period Value New Issues AdjustmentsToAdditionalPaidInCapitalTemporaryEquityStockIssuedDuringPeriodValueNewIssues	-9450000	usd
CY2020	prme	Adjustments To Additional Paid In Capital Temporary Equity Accretion To Redemption Value AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue	1645000	usd
CY2020	prme	Stock Issued During Period Value Collaborative Agreement StockIssuedDuringPeriodValueCollaborativeAgreement	150000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	391000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3410000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2338000	usd
CY2021	prme	Adjustments To Additional Paid In Capital Temporary Equity Stock Issued During Period Value New Issues AdjustmentsToAdditionalPaidInCapitalTemporaryEquityStockIssuedDuringPeriodValueNewIssues	998000	usd
CY2021	prme	Adjustments To Additional Paid In Capital Temporary Equity Accretion To Redemption Value AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue	1468000	usd
CY2021	prme	Adjustments To Additional Paid In Capital Reclassification Of Anti Dilution Obligation Upon Settlement Value AdjustmentsToAdditionalPaidInCapitalReclassificationOfAntiDilutionObligationUponSettlementValue	7536000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1746000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-165367000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-27000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-156240000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	219000	usd
CY2022	prme	Additional Paid In Capital Reclassification Of Related Party Forward Contract Value AdditionalPaidInCapitalReclassificationOfRelatedPartyForwardContractValue	12020000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	395801000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	180189000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6459000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-357000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	316270000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-165367000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3410000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2224000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	568000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	43000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	250000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-715000	usd
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6459000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1746000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	391000	usd
CY2022	prme	Noncash Research And Development Expense For Licenses NoncashResearchAndDevelopmentExpenseForLicenses	0	usd
CY2021	prme	Noncash Research And Development Expense For Licenses NoncashResearchAndDevelopmentExpenseForLicenses	12020000	usd
CY2020	prme	Noncash Research And Development Expense For Licenses NoncashResearchAndDevelopmentExpenseForLicenses	0	usd
CY2022	prme	Noncash Consideration Received Related Party Collaboration Arrangement NoncashConsiderationReceivedRelatedPartyCollaborationArrangement	0	usd
CY2021	prme	Noncash Consideration Received Related Party Collaboration Arrangement NoncashConsiderationReceivedRelatedPartyCollaborationArrangement	0	usd
CY2020	prme	Noncash Consideration Received Related Party Collaboration Arrangement NoncashConsiderationReceivedRelatedPartyCollaborationArrangement	-5360000	usd
CY2022	prme	Noncash Payments To Related Party NoncashPaymentsToRelatedParty	0	usd
CY2021	prme	Noncash Payments To Related Party NoncashPaymentsToRelatedParty	0	usd
CY2020	prme	Noncash Payments To Related Party NoncashPaymentsToRelatedParty	-150000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	9790000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4293000	usd
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-964000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-624000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1867000	usd
CY2022	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	0	usd
CY2021	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	-74319000	usd
CY2020	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	-10904000	usd
CY2022	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	0	usd
CY2021	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	-6681000	usd
CY2020	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	-700000	usd
CY2022	prme	Change In Fair Value Of Related Party Short Term Investment ChangeInFairValueOfRelatedPartyShortTermInvestment	-8128000	usd
CY2021	prme	Change In Fair Value Of Related Party Short Term Investment ChangeInFairValueOfRelatedPartyShortTermInvestment	-391000	usd
CY2020	prme	Change In Fair Value Of Related Party Short Term Investment ChangeInFairValueOfRelatedPartyShortTermInvestment	10867000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	126000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1738000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	885000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	388000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2458000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1185000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	250000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-25873000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	35206000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	302000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-10248000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4330000	usd
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-131827000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34082000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5544000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16095000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4150000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	639000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	123336000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	81980000	usd
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	93000000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	13000000	usd
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	usd
CY2022	prme	Payments For Security Deposits PaymentsForSecurityDeposits	665000	usd
CY2021	prme	Payments For Security Deposits PaymentsForSecurityDeposits	496000	usd
CY2020	prme	Payments For Security Deposits PaymentsForSecurityDeposits	423000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-47096000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-73626000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1062000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4042000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1086000	usd
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	20000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	185317000	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	219000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	181494000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	269278000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34934000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2571000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	161570000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	28328000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198545000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36975000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8647000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201116000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198545000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36975000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	28590000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	12264000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	395800000	usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
CY2022	prme	Settlement Of Anti Dilution Rights SettlementOfAntiDilutionRights	0	usd
CY2021	prme	Settlement Of Anti Dilution Rights SettlementOfAntiDilutionRights	7536000	usd
CY2020	prme	Settlement Of Anti Dilution Rights SettlementOfAntiDilutionRights	0	usd
CY2022	prme	Settlement Of Related Party Forward Contract SettlementOfRelatedPartyForwardContract	12020000	usd
CY2021	prme	Settlement Of Related Party Forward Contract SettlementOfRelatedPartyForwardContract	0	usd
CY2020	prme	Settlement Of Related Party Forward Contract SettlementOfRelatedPartyForwardContract	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	141000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	prme	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	0	usd
CY2021	prme	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	410000	usd
CY2020	prme	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	0	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	969000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	754000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	0	usd
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1468000	usd
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1645000	usd
CY2022	prme	Related Party Transaction Collaboration Agreement Short Term Investment RelatedPartyTransactionCollaborationAgreementShortTermInvestment	0	usd
CY2021	prme	Related Party Transaction Collaboration Agreement Short Term Investment RelatedPartyTransactionCollaborationAgreementShortTermInvestment	0	usd
CY2020	prme	Related Party Transaction Collaboration Agreement Short Term Investment RelatedPartyTransactionCollaborationAgreementShortTermInvestment	5486000	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	357000	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	27000	usd
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187620000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	185420000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36975000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	13496000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	13125000	usd
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201116000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198545000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36975000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-293200000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	293900000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected within these consolidated financial statements include, but are not limited to, revenue recognition, the valuation of the Company’s common stock and stock-based awards, the valuation of preferred stock tranche right liability, the valuation of the anti-dilution obligation and the valuation of the related party forward contract liability. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ materially from those estimates or assumptions.</span></div>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company invests in U.S. Treasury securities and maintains its cash and cash equivalents at high-quality and accredited financial institutions in amounts that could exceed federally </span></div>insured limits. Cash equivalents are invested in money market funds. However, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	120500000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	49500000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13500000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13100000	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1500000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	226812000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2700000	usd
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2800000	usd
CY2021Q1	us-gaap	Prepaid Rent PrepaidRent	100000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	7834000	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	15962000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	133650000	usd
CY2021Q4	prme	Related Party Forward Contract Liability Fair Value Disclosure RelatedPartyForwardContractLiabilityFairValueDisclosure	12020000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	12020000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni Cost EquitySecuritiesFvNiCost	5486000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	2348000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	0	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	7834000	usd
CY2022Q4	prme	Debt And Equity Securities Amortized Cost DebtAndEquitySecuritiesAmortizedCost	104337000	usd
CY2022Q4	prme	Debt And Equity Securities Unrealized Gains DebtAndEquitySecuritiesUnrealizedGains	2348000	usd
CY2022Q4	prme	Debt And Equity Securities Unrealized Loss DebtAndEquitySecuritiesUnrealizedLoss	384000	usd
CY2022Q4	prme	Debt And Equity Securities DebtAndEquitySecurities	106301000	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni Cost EquitySecuritiesFvNiCost	5486000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	10476000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	0	usd
CY2021	prme	Anti Dilution Obligation Achievement Threshold AntiDilutionObligationAchievementThreshold	100000000	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	15962000	usd
CY2021Q4	prme	Debt And Equity Securities Amortized Cost DebtAndEquitySecuritiesAmortizedCost	73751000	usd
CY2021Q4	prme	Debt And Equity Securities Unrealized Gains DebtAndEquitySecuritiesUnrealizedGains	10476000	usd
CY2021Q4	prme	Debt And Equity Securities Unrealized Loss DebtAndEquitySecuritiesUnrealizedLoss	27000	usd
CY2021Q4	prme	Debt And Equity Securities DebtAndEquitySecurities	84200000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	98467000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	68238000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	98467000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	68238000	usd
CY2021	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	-74300000	usd
CY2020	prme	Change In Fair Value Of Preferred Stock Tranche Right Liability ChangeInFairValueOfPreferredStockTrancheRightLiability	-10900000	usd
CY2021	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	-6700000	usd
CY2020	prme	Change In Fair Value Of Anti Dilution Rights ChangeInFairValueOfAntiDilutionRights	-700000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21840000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5543000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2831000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	611000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19009000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4932000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2200000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	43000	usd
CY2022Q4	prme	Accrued License Fee Current AccruedLicenseFeeCurrent	0	usd
CY2021Q4	prme	Accrued License Fee Current AccruedLicenseFeeCurrent	30000000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6529000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2364000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2162000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3830000	usd
CY2022Q4	prme	Accrued Lab Related Supplies And Services Current AccruedLabRelatedSuppliesAndServicesCurrent	1548000	usd
CY2021Q4	prme	Accrued Lab Related Supplies And Services Current AccruedLabRelatedSuppliesAndServicesCurrent	719000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	449000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	279000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10688000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	37192000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	161420799	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	161420799	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	161420799	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	395800000	usd
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	335814000	usd
CY2021Q4	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	51923764	shares
CY2021	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0	usd
CY2022	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0	usd
CY2020	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0	usd
CY2022Q4	prme	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7622758	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	58433916	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6459000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1746000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	391000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-900000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-500000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1900000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	16000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	138000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	16000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	138000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-314000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-928000	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1332000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-650000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	304000	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	535000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-964000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-624000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1867000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-948000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-486000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1867000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.077
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.035
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.385
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.009
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.096
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-1.485
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.029
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.007
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.095
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.300
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.152
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.358
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.007
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.003
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-1.210
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20427000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11365000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7268000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1547000	usd
CY2022Q4	prme	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	13307000	usd
CY2021Q4	prme	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	13584000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1649000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	639000	usd
CY2022Q4	prme	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	7853000	usd
CY2021Q4	prme	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	2843000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	19974000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	279000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1243000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	122000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70600000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29978000	usd
CY2022Q4	prme	Deferred Tax Liabilities Stock Based Compensation DeferredTaxLiabilitiesStockBasedCompensation	0	usd
CY2021Q4	prme	Deferred Tax Liabilities Stock Based Compensation DeferredTaxLiabilitiesStockBasedCompensation	136000	usd
CY2022Q4	prme	Deferred Tax Liabilities Adjustments DeferredTaxLiabilitiesAdjustments	34000	usd
CY2021Q4	prme	Deferred Tax Liabilities Adjustments DeferredTaxLiabilitiesAdjustments	34000	usd
CY2022Q4	prme	Deferred Tax Liabilities Unrealized Gain Loss DeferredTaxLiabilitiesUnrealizedGainLoss	641000	usd
CY2021Q4	prme	Deferred Tax Liabilities Unrealized Gain Loss DeferredTaxLiabilitiesUnrealizedGainLoss	2862000	usd
CY2022Q4	prme	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	8072000	usd
CY2021Q4	prme	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	2936000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8747000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5968000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62132000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25253000	usd
CY2021	prme	Research And Development Costs Capitalized ResearchAndDevelopmentCostsCapitalized	80700000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	300000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25253000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	552000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	36879000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	25253000	usd
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-552000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62132000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25253000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	10999000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4457000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1111000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	222000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1401000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	432000	usd
CY2022	us-gaap	Lease Cost LeaseCost	13511000	usd
CY2021	us-gaap	Lease Cost LeaseCost	5111000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0492
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0210
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	11963000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13035000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3510000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1683000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	566000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	30757000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2012000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	28745000	usd
CY2020	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1000000	usd
CY2021	prme	Collaborative Arrangement Rights And Obligations Development Regulatory And Sales Based Milestone And Royalty Payment Eligibility Term Thereafter CollaborativeArrangementRightsAndObligationsDevelopmentRegulatoryAndSalesBasedMilestoneAndRoyaltyPaymentEligibilityTermThereafter	P2Y
CY2021	prme	Collaborative Arrangement Rights And Obligations Development Regulatory And Sales Based Milestone And Royalty Payment Eligibility Maximum Number Of Targets CollaborativeArrangementRightsAndObligationsDevelopmentRegulatoryAndSalesBasedMilestoneAndRoyaltyPaymentEligibilityMaximumNumberOfTargets	3	target
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121821000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-165367000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3410000	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1468000	usd
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1645000	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	20193000	usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	17284000	usd
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-142014000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-142014000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-184119000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-184119000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5055000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5055000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33891264	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33891264	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12973495	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12973495	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2639717	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2639717	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.19
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.19
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.19
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.19
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.91
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.91
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13213798	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	70281151	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	37713137	shares

Files In Submission

Name	View Source	Status
0001628280-23-007266-index-headers.html	Edgar Link	pending
0001628280-23-007266-index.html	Edgar Link	pending
0001628280-23-007266.txt	Edgar Link	pending
0001628280-23-007266-xbrl.zip	Edgar Link	pending
exhibit1017prime-broadthir.htm	Edgar Link	pending
exhibit1018prime-broadmm.htm	Edgar Link	pending
exhibit1018prime-broadmm001.jpg	Edgar Link	pending
exhibit1018prime-broadmm002.jpg	Edgar Link	pending
exhibit1018prime-broadmm003.jpg	Edgar Link	pending
exhibit1018prime-broadmm004.jpg	Edgar Link	pending
exhibit1018prime-broadmm005.jpg	Edgar Link	pending
exhibit1018prime-broadmm006.jpg	Edgar Link	pending
exhibit1018prime-broadmm007.jpg	Edgar Link	pending
exhibit1018prime-broadmm008.jpg	Edgar Link	pending
exhibit1018prime-broadmm009.jpg	Edgar Link	pending
exhibit1018prime-broadmm010.jpg	Edgar Link	pending
exhibit1018prime-broadmm011.jpg	Edgar Link	pending
exhibit1018prime-broadmm012.jpg	Edgar Link	pending
exhibit1018prime-broadmm013.jpg	Edgar Link	pending
exhibit1018prime-broadmm014.jpg	Edgar Link	pending
exhibit1018prime-broadmm015.jpg	Edgar Link	pending
exhibit1018prime-broadmm016.jpg	Edgar Link	pending
exhibit1018prime-broadmm017.jpg	Edgar Link	pending
exhibit1018prime-broadmm018.jpg	Edgar Link	pending
exhibit1018prime-broadmm019.jpg	Edgar Link	pending
exhibit1018prime-broadmm020.jpg	Edgar Link	pending
exhibit1018prime-broadmm021.jpg	Edgar Link	pending
exhibit1018prime-broadmm022.jpg	Edgar Link	pending
exhibit1018prime-broadmm023.jpg	Edgar Link	pending
exhibit1018prime-broadmm024.jpg	Edgar Link	pending
exhibit1018prime-broadmm025.jpg	Edgar Link	pending
exhibit1018prime-broadmm026.jpg	Edgar Link	pending
exhibit1018prime-broadmm027.jpg	Edgar Link	pending
exhibit1018prime-broadmm028.jpg	Edgar Link	pending
exhibit1018prime-broadmm029.jpg	Edgar Link	pending
exhibit1018prime-broadmm030.jpg	Edgar Link	pending
exhibit1018prime-broadmm031.jpg	Edgar Link	pending
exhibit1018prime-broadmm032.jpg	Edgar Link	pending
exhibit1018prime-broadmm033.jpg	Edgar Link	pending
exhibit1018prime-broadmm034.jpg	Edgar Link	pending
exhibit1018prime-broadmm035.jpg	Edgar Link	pending
exhibit1018prime-broadmm036.jpg	Edgar Link	pending
exhibit1018prime-broadmm037.jpg	Edgar Link	pending
exhibit1018prime-broadmm038.jpg	Edgar Link	pending
exhibit1018prime-broadmm039.jpg	Edgar Link	pending
exhibit1018prime-broadmm040.jpg	Edgar Link	pending
exhibit1018prime-broadmm041.jpg	Edgar Link	pending
exhibit1018prime-broadmm042.jpg	Edgar Link	pending
exhibit1018prime-broadmm043.jpg	Edgar Link	pending
exhibit1018prime-broadmm044.jpg	Edgar Link	pending
exhibit1018prime-broadmm045.jpg	Edgar Link	pending
exhibit1018prime-broadmm046.jpg	Edgar Link	pending
exhibit1018prime-broadmm047.jpg	Edgar Link	pending
exhibit1018prime-broadmm048.jpg	Edgar Link	pending
exhibit1018prime-broadmm049.jpg	Edgar Link	pending
exhibit1018prime-broadmm050.jpg	Edgar Link	pending
exhibit1018prime-broadmm051.jpg	Edgar Link	pending
exhibit1018prime-broadmm052.jpg	Edgar Link	pending
exhibit1018prime-broadmm053.jpg	Edgar Link	pending
exhibit1018prime-broadmm054.jpg	Edgar Link	pending
exhibit1018prime-broadmm055.jpg	Edgar Link	pending
exhibit1018prime-broadmm056.jpg	Edgar Link	pending
exhibit1018prime-broadmm057.jpg	Edgar Link	pending
exhibit1018prime-broadmm058.jpg	Edgar Link	pending
exhibit1018prime-broadmm059.jpg	Edgar Link	pending
exhibit1018prime-broadmm060.jpg	Edgar Link	pending
exhibit1018prime-broadmm061.jpg	Edgar Link	pending
exhibit1018prime-broadmm062.jpg	Edgar Link	pending
exhibit1018prime-broadmm063.jpg	Edgar Link	pending
exhibit1018prime-broadmm064.jpg	Edgar Link	pending
exhibit1018prime-broadmm065.jpg	Edgar Link	pending
exhibit1018prime-broadmm066.jpg	Edgar Link	pending
exhibit1018prime-broadmm067.jpg	Edgar Link	pending
exhibit1018prime-broadmm068.jpg	Edgar Link	pending
exhibit1018prime-broadmm069.jpg	Edgar Link	pending
exhibit1018prime-broadmm070.jpg	Edgar Link	pending
exhibit1018prime-broadmm071.jpg	Edgar Link	pending
exhibit1018prime-broadmm072.jpg	Edgar Link	pending
exhibit1018prime-broadmm073.jpg	Edgar Link	pending
exhibit1018prime-broadmm074.jpg	Edgar Link	pending
exhibit1018prime-broadmm075.jpg	Edgar Link	pending
exhibit1018prime-broadmm076.jpg	Edgar Link	pending
exhibit1018prime-broadmm077.jpg	Edgar Link	pending
exhibit1018prime-broadmm078.jpg	Edgar Link	pending
exhibit1018prime-broadmm079.jpg	Edgar Link	pending
exhibit1018prime-broadmm080.jpg	Edgar Link	pending
exhibit1018prime-broadmm081.jpg	Edgar Link	pending
exhibit1018prime-broadmm082.jpg	Edgar Link	pending
exhibit1018prime-broadmm083.jpg	Edgar Link	pending
exhibit1018prime-broadmm084.jpg	Edgar Link	pending
exhibit1018prime-broadmm085.jpg	Edgar Link	pending
exhibit1018prime-broadmm086.jpg	Edgar Link	pending
exhibit1018prime-broadmm087.jpg	Edgar Link	pending
exhibit1018prime-broadmm088.jpg	Edgar Link	pending
exhibit1018prime-broadmm089.jpg	Edgar Link	pending
exhibit1018prime-broadmm090.jpg	Edgar Link	pending
exhibit1018prime-broadmm091.jpg	Edgar Link	pending
exhibit231pwcconsent.htm	Edgar Link	pending
exhibit311certification.htm	Edgar Link	pending
exhibit312certification.htm	Edgar Link	pending
exhibit321certification.htm	Edgar Link	pending
exhibit322certification.htm	Edgar Link	pending
exhibit43descriptionofsecu.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prme-20221231.htm	Edgar Link	pending
prme-20221231.xsd	Edgar Link	pending
prme-20221231_g1.jpg	Edgar Link	pending
prme-20221231_g10.jpg	Edgar Link	pending
prme-20221231_g11.jpg	Edgar Link	pending
prme-20221231_g12.jpg	Edgar Link	pending
prme-20221231_g13.jpg	Edgar Link	pending
prme-20221231_g14.jpg	Edgar Link	pending
prme-20221231_g15.jpg	Edgar Link	pending
prme-20221231_g16.jpg	Edgar Link	pending
prme-20221231_g17.jpg	Edgar Link	pending
prme-20221231_g18.jpg	Edgar Link	pending
prme-20221231_g19.jpg	Edgar Link	pending
prme-20221231_g2.jpg	Edgar Link	pending
prme-20221231_g20.jpg	Edgar Link	pending
prme-20221231_g21.jpg	Edgar Link	pending
prme-20221231_g22.jpg	Edgar Link	pending
prme-20221231_g23.jpg	Edgar Link	pending
prme-20221231_g24.jpg	Edgar Link	pending
prme-20221231_g25.jpg	Edgar Link	pending
prme-20221231_g26.jpg	Edgar Link	pending
prme-20221231_g27.jpg	Edgar Link	pending
prme-20221231_g28.jpg	Edgar Link	pending
prme-20221231_g29.jpg	Edgar Link	pending
prme-20221231_g3.jpg	Edgar Link	pending
prme-20221231_g30.jpg	Edgar Link	pending
prme-20221231_g31.jpg	Edgar Link	pending
prme-20221231_g32.jpg	Edgar Link	pending
prme-20221231_g33.jpg	Edgar Link	pending
prme-20221231_g34.jpg	Edgar Link	pending
prme-20221231_g35.jpg	Edgar Link	pending
prme-20221231_g36.jpg	Edgar Link	pending
prme-20221231_g37.jpg	Edgar Link	pending
prme-20221231_g38.jpg	Edgar Link	pending
prme-20221231_g39.jpg	Edgar Link	pending
prme-20221231_cal.xml	Edgar Link	unprocessable
prme-20221231_def.xml	Edgar Link	unprocessable
prme-20221231_g4.jpg	Edgar Link	pending
prme-20221231_g40.jpg	Edgar Link	pending
prme-20221231_g41.jpg	Edgar Link	pending
prme-20221231_g42.jpg	Edgar Link	pending
prme-20221231_g43.jpg	Edgar Link	pending
prme-20221231_g44.jpg	Edgar Link	pending
prme-20221231_g45.jpg	Edgar Link	pending
prme-20221231_g46.jpg	Edgar Link	pending
prme-20221231_g47.jpg	Edgar Link	pending
prme-20221231_g48.jpg	Edgar Link	pending
prme-20221231_g49.jpg	Edgar Link	pending
prme-20221231_g5.jpg	Edgar Link	pending
prme-20221231_g50.jpg	Edgar Link	pending
prme-20221231_g51.jpg	Edgar Link	pending
prme-20221231_g52.jpg	Edgar Link	pending
prme-20221231_g53.jpg	Edgar Link	pending
prme-20221231_g54.jpg	Edgar Link	pending
prme-20221231_g6.jpg	Edgar Link	pending
prme-20221231_g7.jpg	Edgar Link	pending
prme-20221231_g8.jpg	Edgar Link	pending
prme-20221231_g9.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
prme-20221231_pre.xml	Edgar Link	unprocessable
prme-20221231_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
prme-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRME
Prime Medicine Inc Stock $prme

2023 Q1 Form 10-K Financial Statement

#000162828023007266 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRME Prime Medicine Inc Stock $prme

2023 Q1 Form 10-K Financial Statement

#000162828023007266 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRME
Prime Medicine Inc Stock $prme